I'm excited today, Herve, because we're going to talk through something that I've been wanting to understand when it comes to manufacturing. What is China doing right? What can we learn from your experiences there? But also you're talking about tech bio, which I've never heard before the phrase. But I mean, it's obviously something we need in our lives to live longer, to live better. I mean, everyone Everyone's talking now about AI and robotics, and it seems like you're putting a lot of things together. So let's go back to your time with China. What were some of the learnings that you had around speed, efficiency, and manufacturing?
Yeah, well, hello, Dan. So I'm very pleased to chat with you today. Yeah, well, I'm an engineer by design. I started my career in China. This is back 30 years ago. I'm a bit old now. It's back 94 to 99. I was doing that, basically developing the business for a French industrial group, which was the Dutrish. What we were proposing to China were some chemical reactors which are used for the pharmaceutical synthesis. At that time, China, back 30 years ago, I mean, almost everybody was driving bicycles, almost no cars there, and you didn't have so much as high rise, skyrise, skyscrapers in Shanghai. It was only the TV tower in Shanghai. I was amazed because all the industrial firms that I was visiting there, all of them had a very clear vision of where they wanted to go. They were very interested in new technologies and partnering with innovation, new equipment, and basically modernizing their factories. All these factories were very old and with very poor equipment, very poor performance, very poor capabilities. The thing that was very interesting is that each time one factory would decide to move ahead, they would execute the plant like Speedy Gonzales.
The speed was of the essence everywhere. So once they decide to go, then they make it happen, and very quickly, much far quickly than what we could do in the West at that time. And at At the time, 30 years ago, we were much faster in the West than we are today. And this was absolutely incredible. So the thing was the speed and the vision. They were very smart, very, very clear where they were, where they wanted to go, and then execute a plan with a huge amount of speed. And what I can tell you is when I left China in '99, everything that is happening today was was already written in the plan. It was written. They knew at that time that they wanted to... They already understood that their industry, our industry in the US or in Europe, the essential brick of the industry is the automotive industry. And they had decided at that time that they would go after this industry. And basically, what you can notice today is that they actually executed the and how their electric cars with BYD and others are amongst the best in the world, if not the best.
And they made that as an execution plan. And this is very key. Basically, it was very clear to me that that plan was clearly driven by some sovereignty, was clearly driven by innovation, by investment. Every time a Chinese company would build a factory state of the art with the modern technology, then they would replicate, replicate that in other provinces. It's clear that they just executed a plan. This was a very lessons learned for me was industry is having a right prospective, know where you want to go, and then execute a plan, being very patient in execution, but very fast on a day-to-day basis in order to execute that plan. That has been, I would say, the real kickoff of my career.
It's amazing to think only 30 years, all that advancement has happened. The fact that they planned it, we could take a lot away. Like you said, as business owners, we could take a lot understanding away of long-term planning because I think we so caught in the minutiae of day to day. We're not always planning 20, 30, 40, 50 years out. We're just planning in the next five minutes. I've heard they have each city manufactures something different. One day, I'd like to go to Shanghai. I've heard it's incredibly advanced technology and all the robotics. I love BYD. I hate to say it, but it might be my favorite EV car. It's incredible what they've done with that. You get back to France, and you're in my favorite city in France, which is Lyon right now. But you get back to France and you start Maison MGA. What was the problem that you were solving?
Maison MGA started a bit later than that. In the meantime, between '99 and 2010, where I started Maison MGA, what happened is that I've been onboarded back in the industry. And basically, I've been, I would say, coming from machine to integrated system and complex engineering systems, including turnkey greenfield factories, I had to basically get into the complexity of building a greenfield plant. I was very, very impressed at that time because I followed a project which we which we incorporated in Wuxi, which is 100 km basically from Shanghai. When we decided to invest and build a greenfield factory in Wussi, we signed the land three months after the factory was finished. Again, speed, but also understanding the complexity of engineering, a complete process plant, basically aligning all the necessary bricks for the technology and building that for the future with already a vision of different workflows necessary and basically the process necessary to have it a performance. And so I did that for about 10 years, first in the UK and then in France, and then built factories all around in the US, everywhere on the five continents. I was running an engineering firm at the time making so process plant, both for the pharmaceutical industry, making vaccines, mixing plasma, blood plasma, fractionation, and all this complex engineering for bioprocessing.
Those experiences, China, and then making those complex systems engineering, drove me to We could see at that time that the digital was coming up. Robotics was already deployed in the car industry and some other industries, but very little, very seldom in the life science industry. Almost no robots were there. I decided to basically put all our energy into those complex systems engineering into clean environments. So basically putting those complex engineering into clean rooms in order to serve mainly the life science industry. And so that's what we've been doing with MGA. So putting robots, tailor-made machines, instruments in order to address those complex engineering and put more and more robotics also with all the digitalization, which was already happening back 15 years ago. So that's where we are.
Yeah. Can you talk more about, and thank you for sharing that, this tech bio, why is tech bio even important? And I'm very interested about robotics. I feel like everyone is talking about, we will all have robots in our homes. You're going to look outside and robots will just be walking around everywhere. So I'd love to understand your perspective around how robotics is changing all these industries. But I think start by what is tech bio?
So tech bio is not like biotech. Biotech is basically you put in a pan some media, and then you basically are growing life into a pan. This is biotech. Bioprocessing. You make first cell culture, and then you clarify the cell culture with downstream processing, with ultra-futration, chromatography, and those type of thing. Then you put this in a vial into a fill-and-finish process. This is biotech. Biotech has been developed over the past 20, 25 years, very intensively into the vaccines business. And basically, the trend in biotech was to make bioreactors bigger and bigger and bigger. And of course, the ultimate of this is the mRNA vaccines that we have been developed very, very fast during COVID. And that has given a very huge, I would say, acceleration into this biotech business. And then what happened is that opening the mRNA application, also in parallel to that, has been developed all these cell and gene therapies. And basically, the volumes which we consider for those type of biotherapies are down to a single vial, one vial, one patient. I mean, those big bioreactors are no longer relevant. Then tech bio is basically putting all the engineering the complex engineering capability to personalize medicine and basically reverse this tech all engineering capabilities to bio, to biology.
Basically, the engineer doing the engineering for biology. In tech bio, you have all these instruments, processing instruments to make those personalized medicine. You have all the I would say the instruments for IVD, for in vitro diagnosis. You have also all these implants which have some robots embedded into the body. You have sensors that you can implant in the brain. You have also all the artificial intelligence that can be used, for instance, on those heart diagrams. You can analyze this with image and then basically detect errors or special patterns that can give you some idea. And further to that, you also with digital, you can have a loop with the patient because if you develop one particular drug for one patient, you can also, through his smartphone, you can also report all the answer of how he feels on a day-to-day basis through simple questions. And this also helps on improving the treatment for the patient. So basically, all this engineering capability, whether hardware, software, driven to one patient and looping with the patient, that is TechBio.
Wow. How do you see... The fact that we could put robots in people and it could maybe solve problems inside them or do surgeries or whatever other, put it in our brain. What excites you the most about when you think of robotics in tech bio health care, but what also scares you the most?
What we can see What we know with those generative AI is that you basically can foresee that some disease are going to be treated. So we are going to find solutions for cancer, for all brain disease. If you make prospective in the next 20 years, 25 years, if we are back in 2050, in 2050, it's very clear that almost all the known disease of today will have treatment. That's very clear. Now, the downside of this is, of course, some people with the regeneration of cellular tissues, you can imagine that you can basically replace your heart. If there is a problem, you can replace your liver, you can replace your muscles, you can replace one eye and so on. So possibly some people with a lot of money, they could maybe live 500 years or 1,000 years. So this is, of course, not very acceptable ethically. I think we will have to define as a society, as a world society, we will have to define some limits where this is no longer acceptable. This we should not do. We should not play with life in terms of what God gave us. We need to make sure that all these new technologies respect life, respect humanity.
That's a frontier, a border that has to defined. But on the other hand, you will no longer have those five years old children that die of cancer. This is absolutely insane in terms of... I mean, this cannot be accepted. If we manage to save lives that have to be saved, this is, of course, an ultimate dream, and this is what I'm working You were questioning about my vision about robotics. I see robots as a tool, of course, a pen Very nicely drawing or writing a book. You can also use it very badly. It's the same for AI, it's the same for robotics, it's the same for tech bio. All these have to remain tools for the help of a better living of humanity. And this is what I'm striving for. I, of course, do not accept the idea of technology compromising life or compromising morality. This is my limit.
Maybe I want to live to 300. I don't know about 500, but it reminds me of CRISPR like a decade I know CRISPR was just becoming a thing publicly, and they were talking about the ethics, and should you clone things? There's so many things that they were talking about, but it almost seems like we're in an interesting age, where there's so many technologies coming together as one. There's so many things that... You said we could possibly cure cancer and diseases and fix things. How incredible is that? People can live a better life. But of course, there's always people that might do something bad with it. But the fact that we can do that excites me a lot. If people want to get in touch with you, it's fascinating, right? But if people want to get in touch with you, they want to find out more about Maison, about what you're working on, maybe some partnerships, learn more, how can they do so?
Can give you a few examples of what we've done recently. For instance, we developed an instrument that is working on chips. We did that with the startup called Stila Technologies, which has been acquired by a company in California which is called Bio-RAD. Maybe you know that company. They made an in vitro diagnostic instrument, an IVD instrument. This allows basically to analyze 8 milliliter of a solution, explore those 8 milliliter into 20 1,000 nanodroplets. Each of these nanodroplets individually become a PCR reactor. You can detect positive or negative, basically any DNA trace that you would look in that. And that, of course, allows for a much more precise diagnostic. And you can, for instance, look during a cancer treatment. The oncologist can basically check whether the particular vial that he has injected in the patient is efficient or not, and if the cell tumor, the tumourous cell have been reduced in numbers or if they have increased. And that, of course, is considerably increasing the efficiency of the treatment of the patient. This is one. Another one, we're working with another company that has recently deal with Vertex. You know, Vertex is a very advanced R&D company in cell therapy.
They have made a deal with the tree frog therapeutics. Here they are making a cell encapsulation in order to basically the first divisions of the cells being very, very nicely arranged in 3D in a capsule like in an egg. Therefore, the quality of the first division, which are very, very critical for cell therapy, are much improved. We are developing this technology for them. Of course, we work together. But these are the types of instruments that we are working on. This is extremely exciting because all these IPS-based cell therapy are incredibly promising. It's clear that we are going to completely change. It's a real game changer in biotherapies.
I mean, this is amazing. I can't wait. Super exciting. 20, 30 years from now, our world is going to be so different. I hope it's for the good. And you're going to look back and say, you were a part of it. That's your legacy right there. You completely change the world.
I am very optimistic, and I prefer to be optimistic and being wrong rather than pessimistic and being right.
Is that a French thing or is that just you?
No, This is not a French thing. This is something I forgot who said that, but it doesn't matter. It's a mindset. The mindset is if you make prospective, I I think progress can really change our lives, can change also all the issues that need to be addressed. There are in the jaw a number of innovations that we can really put together and reduce all this carbon footprint of the industry and transport. I think the big, big challenge as a humanity is to basically make sure that the poor countries increase their life standards into an acceptable level. Basically, the rich countries also increase their standard of living in order to live better, longer, happier. I think we have everything in the jaw with all these new technologies to make this happen. I'm very excited to see this coming.
Hopefully, as humans, sometimes we have the habit of screwing things up. So I want to be optimistic like yourself that we are going to do the right thing. It's going to be great. I love the level playing field, right? Like you're saying, certain countries might have issues that with whatever that is, they can solve those with uplift that country, uplift the people. I mean, hopefully this is going to spread everywhere. But thank you so much, by the way, President of Matezone. I appreciate your time today. I'm excited for the future.
Thank you, Dan. I'm very excited.
Daniel Robbins interviews Hervé de Malliard about the manufacturing mindset he learned while building industrial projects in China from 1994 to 1999 and how that shaped his approach to building complex engineered systems in healthcare. Hervé shares why Maison MGA focuses on integrating robotics and instrumentation into cleanroom environments to support life science workflows, and why TechBio will redefine medicine through personalization, diagnostics, and continuous patient feedback loops.
Key Discussion Points:Hervé describes how Chinese manufacturers had clear long term plans and executed factory builds with extreme speed, noting that today’s outcomes were “already written in the plan” when he left in 1999. He explains how his career evolved from chemical reactors and greenfield factories to designing complex bioprocessing plants and eventually bringing robotics into life sciences where adoption was once minimal. Hervé defines TechBio as engineering applied to biology, shifting from large bioreactors toward individualized therapies like cell and gene treatments where one vial can mean one patient. He outlines the upside of AI and robotics curing diseases and improving lives, while warning that society must set ethical boundaries so technology remains a tool that protects humanity rather than compromising it.
Takeaways:A core theme from the episode is that winning manufacturing and innovation comes from vision plus relentless execution, not just ideas. TechBio represents a major inflection point where robotics, instruments, and AI enable personalized care, better diagnostics, and faster iteration in treatment through real patient feedback. Hervé’s line in the sand is clear: progress must save lives and improve living standards, but it cannot become a race to exploit life extension or abandon ethics. Maison MGA’s work shows how “complex engineering” is becoming the backbone of biotech and healthcare sovereignty, turning labs and therapies into scalable, precise systems.
Closing Thoughts:Founder’s Story captures the rare intersection of industrial strategy and human stakes: how we build faster, and why we must build responsibly. Hervé leaves listeners with optimism that the technologies now converging can uplift global living standards, cure diseases, and create a better future, as long as society chooses the right limits. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.